{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy versus Treatment of Physician’s Choice in Hormone Receptor positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04)","item":"https:\/\/www.regionalcancercare.org\/trials\/an-open-label-randomized-phase-3-study-to-evaluate-patritumab-deruxtecan-monotherapy-versus-treatment-of-physicians-choice-in-hormone-receptor-positive-her2-negative-unresectable-locally-advanced\/#breadcrumbitem"}]}